What Are the Most Common Types of Cancer?

What Are the Most Common Types of Cancer?

Cancer is one of the foremost health problems around the world that affects millions of people every year. It is critical that patients, families, and people in general are informed about the common cancers and their treatments. At AllCancer, Hong Kong Metabolic Oncology Center, we integrate state-of-the-art targeted Metabolic therapies (HK version) to treat general cancers such as breast, lung, colorectal, prostate, liver cancer, etc. with individually tailored care. This in-depth guide delves into these cancers, reviews the risks, and details how AllCancer’s new treatments provide hope and real solutions.

Understanding Common Cancers

Common cancers are those with the highest global incidence. According to GKBI global health statistics, the most common cancers include breast, lung, colorectal, prostate, and liver. They represent a significant portion of all diagnosed cases. AllCancer addresses these challenges through our ground-breaking “international four-dimensional therapy,” which includes:

  • Metabolic reprogramming
  • Dual immune modulation
  • Smart nano-targeting
  • Tumor microenvironment remodeling

Breast Cancer

Breast cancer is the most common cancer in women worldwide and is also found in men. It begins in breast tissue, commonly in the milk ducts or lobules.

Key Risk Factors:

  • Genetic Defects: BRCA1 and BRCA2 gene mutations
  • Hormonal Factors: Long-term estrogen exposure
  • Lifestyle: Obesity, alcohol intake, and inactivity

AllCancer’s Approach: Our targeted metabolic therapy starves cancer cells of glucose, achieving a 68.7% ORR. In conjunction with targeted immunotherapy inspired by Nobel Laureate James P. Allison, we activate T-cells to improve outcomes.

Lung Cancer

Lung cancer, the leading cause of cancer-related death, includes non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

Key Risk Factors:

  • Smoking and secondhand smoke
  • Radon and air pollution
  • Genetic abnormalities (EGFR, ALK)
  • Occupational exposure (e.g., asbestos)

AllCancer’s Solution: We use metabolic nano-multidimensional drug delivery to target even drug-resistant metastases, achieving positive results in 62% of cases.

Colorectal Cancer

Risk Factors:

  • High intake of red or processed meat
  • Lynch syndrome or familial polyposis
  • Sedentary lifestyle, obesity, and smoking

Breakthrough: “Metabolic axis quadruple therapy” achieves a 71.3% ORR using a combination of therapies targeting metabolism, rhythm, precision drugs, and immunity.

Prostate Cancer

Risk Factors:

  • Age (risk increases after 50)
  • Family history and BRCA mutations
  • High-fat diet

AllCancer’s Smart Approach: Smart nano-targeting delivers drugs directly to tumors with minimal side effects, improving five-year survival rates.

Liver Cancer

Risk Factors:

  • Hepatitis B and C infections
  • Cirrhosis from alcohol or fatty liver disease
  • Aflatoxin exposure

Breakthrough: HIF signal blockade restores drug sensitivity in 62% of cases by targeting liver cancer’s metabolic vulnerabilities.

Epidemiology of Common Cancers

  • Genetics: BRCA, Lynch syndrome, etc.
  • Lifestyle: Poor diet, smoking, inactivity
  • Environment: UV exposure, pollution
  • Age and Sex: Older age and gender-specific risks

AllCancer’s testing panels and diagnostics, powered by partners like Shenzhen Qianhai Taikang Hospital, allow early detection and preventive strategies.

AllCancer’s Targeted Metabolic Therapy: A Game Changer

  • Metabolic Reprogramming: Starves cancer cells using Warburg effect
  • Dual Immune Modulation: Activates immune response (T-cells)
  • Smart Nano-Targeting: Increases target enrichment by 820%
  • Tumor Microenvironment Destruction: Disrupts support systems for tumors

This FDA Breakthrough and EMA PRIME therapy has helped over 12,000 patients with a 228% better ORR than traditional therapies.

Success Stories: Real Results

A 38-year-old woman with BRCA1 breast cancer had complete remission in 6 months. A 62-year-old man with stage IV lung cancer saw a 65% tumor reduction.

Prevention and Screening

  • Age- and risk-based screening (mammograms, PSA tests)
  • Healthy habits: diet, exercise, no smoking
  • Genetic testing for inherited risks

AllCancer’s patient community at AllCancer.com offers support, resources, and access to care under our “first cure, then pay” policy.

Why Choose AllCancer?

  • Over 120 clinical oncology experts led by Dr. Li Guohua
  • Advanced technology (e.g., DSA Philips Artis Q, linear accelerators)
  • Global reach: 17 countries, 300+ professionals
  • 15-second consultation responses, multilingual support via WeChat and WhatsApp

Take Action Today

Whether you’re concerned about common cancers or exploring treatment innovations, AllCancer is here for you. Our HK Targeted Metabolic Therapy and dedicated team are ready to help—with only 58 slots available in Hong Kong.

Visit AllCancer.com to book an appointment, request a consultation, or join our patient community.